Literatur
- 01
Concato J, Wells C K, Horwitz R I, Penson D, Fincke G, Berlowitz D R, Froehlich D,
Blake G, Vickers M A, Gehr G A, Raheb N H, Sullivan G, Peduzzi P.
The effectiveness of screening for prostate cancer: a nested case-control study.
Archives of Internal Medicine.
2006;
166
(1)
38-43
- 02
McLeod D G, Iversen P, See W A, Morris T, Armstrong J, Wirth M P.
Casodex Early Prostate Cancer Trialists' Group: Bicalutamide 150 mg plus standard
care vs standard care alone for early prostate cancer.
BJU Int.
2006;
97
(2)
247-54
- 03
Thompson I M, Goodman P J, Tangen C M, Lucia M S, Miller G J, Ford L G, Lieber M M,
Cespedes R D, Atkins J N, Lippman S M, Carlin S M, Ryan A, Szczepanek C M, Crowley J J,
Coltman Jr C A.
The influence of finasteride on the development of prostate cancer.
N Engl J Med.
2003;
349
(3)
215-24
- 04
Saad F, Gleason D M, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J L, Vinholes J J,
Goas J A, Zheng M.
Zoledronic Acid Prostate Cancer Study Group: Long-term efficacy of zoledronic
acid for the prevention of skeletal complications in patients with metastatic
hormone-refractory prostate cancer.
J Natl Cancer Inst.
2004;
96
(11)
879-82
- 05 Schmitz-Dräger B J, Ebert T, Höfer R, Zaun S. MännerKüche. Marburg; Verlag im Kilian
2001
Korrespondenzadresse
Prof. Dr. med. Bernd J. Schmitz-Dräger
EuromedClinic, Abteilung für Urologie
Europa-Allee 1
90763 Fürth
